The clinical benefits of multi-kinase inhibitors (such as Sorafenib and Lenvatinib) that target VEGF and its receptors have not been as good as initially expected, perhaps partly because of the off-target effect of anti-tumor agents (99). Here, VEGFA is linked to neoplasm.